Nirmatrelvir; ritonavir - Generic Drug Details

What are the generic drug sources for nirmatrelvir; ritonavir and what is the scope of patent protection?

Nirmatrelvir; ritonavir is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nirmatrelvir; ritonavir has seventy-three patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for nirmatrelvir; ritonavir

International Patents:	73
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for nirmatrelvir; ritonavir
DailyMed Link:	nirmatrelvir; ritonavir at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for nirmatrelvir; ritonavir

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for nirmatrelvir; ritonavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Traws Pharma, Inc.	PHASE2
Pfizer	PHASE1
National Taiwan University Hospital	NA

See all nirmatrelvir; ritonavir clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for nirmatrelvir; ritonavir

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for nirmatrelvir; ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PAXLOVID (COPACKAGED)	nirmatrelvir; ritonavir	TABLET;ORAL	217188-001	May 25, 2023		RX	Yes	Yes
Pfizer	PAXLOVID (COPACKAGED)	nirmatrelvir; ritonavir	TABLET;ORAL	217188-001	May 25, 2023		RX	Yes	Yes	11,351,149		Y	Y
Pfizer	PAXLOVID (COPACKAGED)	nirmatrelvir; ritonavir	TABLET;ORAL	217188-001	May 25, 2023		RX	Yes	Yes	11,541,034
Pfizer	PAXLOVID (COPACKAGED)	nirmatrelvir; ritonavir	TABLET;ORAL	217188-001	May 25, 2023		RX	Yes	Yes

International Patents for nirmatrelvir; ritonavir

Country	Patent Number	Title	Estimated Expiration
South Korea	102481876
Israel	299071
Mexico	2021013679
Philippines	12021552851	NITRILE-CONTAINING ANTIVIRAL COMPOUNDS
Serbia	63714	JEDINJENJA KOJA SADRŽE NITRIL KORISNA KAO ANTIVIRUSNA SREDSTVA ZA LEČENJE INFEKCIJE KORONAVIRUSOM (NITRILE-CONTAINING COMPOUNDS USEFUL AS ANTIVIRAL AGENTS FOR THE TREATMENT OF A CORONAVIRUS INFECTION)
Chile	2021002965
Poland	3953330

Market Overview and Financial Trajectory of Nirmatrelvir; Ritonavir Combination

Last updated: February 16, 2026

Introduction

Nirmatrelvir combined with ritonavir forms the antiviral medication Paxlovid, developed by Pfizer to treat COVID-19. The drug gained emergency approval and later full approval in numerous jurisdictions, including the U.S. and Europe. Its market success and financial prospects depend on clinical efficacy, patent protections, manufacturing capacity, competitive landscape, and global demand shifts.

Market Dynamics

Regulatory Status and Approvals

• Approved in the U.S. by the Food and Drug Administration (FDA) in December 2021 under Emergency Use Authorization (EUA) for treating mild to moderate COVID-19 in high-risk patients.
• Received full FDA approval in January 2023.
• Approved in the European Union by the European Medicines Agency (EMA) in late 2022.
• Other regions such as Japan, Canada, and Australia approved through respective regulatory pathways.

Demand Drivers

• The COVID-19 pandemic remains a global health event, with ongoing emergence of variants impacting hospitalization and mortality rates.
• Paxlovid's clinical efficacy reduces hospitalization risk by approximately 89% in high-risk patients, establishing it as a key oral antiviral option.
• Rapid adoption in outpatient settings reduces strain on healthcare systems.

Supply Chain and Manufacturing Capacity

• Pfizer scaled manufacturing capacity rapidly, targeting production of over 120 million courses annually by early 2023.
• Efforts are underway to expand supply via licensing agreements with generic manufacturers in low- and middle-income countries.
• Potential constraints exist related to raw material availability and manufacturing bottlenecks at particular sites.

Competitive Landscape

• Other products include Merck’s molnupiravir (Lagevrio) and similar oral antivirals under development.
• Molnupiravir's varied efficacy (~30-50% reduction in hospitalization risk) positions Paxlovid as the preferred treatment in high-risk cases.
• The emergence of new variants raises concerns over long-term efficacy, potentially affecting market share.

Pricing and Reimbursement

• In the U.S., EUA for Paxlovid set a ceiling price at $530 per treatment course.
• Actual negotiated prices with payers and government programs may differ.
• In other territories, pricing reflects local health policies, patent protections, and negotiation outcomes.

Financial Trajectory

Revenue Performance

• Pfizer reported $12.4 billion in Paxlovid sales in 2022, representing a significant upward shift from near zero pre-pandemic.
• The drug contributed approximately 25% of Pfizer's total revenue for 2022.
• Year-over-year growth was over 500% during the peak pandemic period, followed by stabilization as demand matured.

Forecasted Sales

Year	Estimated Revenue (USD billions)	Assumptions
2023	$8.0 – $10.0	Slower growth as pandemic wanes; improved access in developing countries
2024	$4.0 – $6.0	Diminishing demand; emergence of new variants and competition
2025	$2.0 – $4.0	Market stabilization; potential decline without new indications

Profitability Outlook

• Gross margins are estimated at around 80% due to Pfizer's manufacturing efficiencies.
• Operating margins depend on marketing, R&D, and supply chain costs.
• Future profitability hinges on patent protection expiry, potential generic competition, and the evolution of COVID-19 treatment protocols.

Patent and Licensing

• Patent protection extends into the late 2020s, providing revenue exclusivity.
• Licensing agreements with generic manufacturers in countries like India enable lower-cost access, impacting profitability in those regions.

Long-term Considerations

• The potential for Paxlovid to be repurposed for other viral infections remains unclear but could extend its financial viability.
• The development of oral antivirals with broader spectra of activity may threaten market dominance.
• Pfizer's pipeline investments in COVID-19 therapeutics could influence future revenue streams.

Key Market Risks

• Emergent variants reducing drug efficacy.
• Changes in treatment guidelines or clinical practices.
• Patent expiration and increased generic competition.
• Global access issues due to pricing and manufacturing constraints.

Summary

The pharmaceutical market for nirmatrelvir; ritonavir demonstrates significant initial revenue, driven by EUA and full approval in multiple regions. While Pfizer achieved rapid market penetration, future revenue depends on the pandemic’s progression, competitive challenges, and manufacturing scalability. The product's long-term profitability faces potential decline post-patent expiry, unless new indications emerge or related formulations are developed.

Key Takeaways

• Paxlovid generated over $12 billion in sales in 2022, primarily due to high efficacy and urgent demand.
• Supply chain capacity expansion and licensing aim to improve global access.
• Revenue projections indicate a decline starting in 2024, aligning with pandemic resolution trends.
• Competition from molnupiravir and future antivirals could impact market share.
• Patent protections provide revenue exclusivity into the late 2020s, with generic licensing affecting profitability in some regions.

FAQs

1. How sustainable are Paxlovid's revenues post-pandemic?

   Revenues are expected to decline as COVID-19 becomes endemic, with potential for continued demand in high-risk populations and new indications.

2. What factors influence Pfizer's ability to maintain profitability?

   Patent protection, manufacturing capacity, regulatory approvals, competition, and global access critically shape profitability.

3. Are there upcoming clinical developments that could alter market dynamics?

   Yes. Trials for Paxlovid in other viral infections and combination therapies may influence its long-term role.

4. How does generic licensing impact Pfizer’s future earnings?

   Licensing in low-income countries allows access but reduces margins. Patent protections in developed markets preserve higher profitability in those regions.

5. What risks exist from emerging COVID-19 variants?

   Variants with mutations in the drug’s target proteins could decrease efficacy, prompting the development of next-generation antivirals.

References

[1] Pfizer. Paxlovid EUA Fact Sheet, 2022.

[2] FDA. Approval letter for Paxlovid, 2023.

[3] European Medicines Agency. Paxlovid approval details, 2022.

[4] Pfizer. 2022 annual report.

[5] Market research reports from IQVIA and EvaluatePharma, 2022.